Man Group’s RAPT Therapeutics RAPT Stock Holding History

Man Group’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-18,802	Closed	-$637K	–	2542
2025 Q4	$637K	Buy	+18,802	New	+$584K	﹤0.01%	1821
2023 Q1	–	Sell	-4,053	Closed	-$642K	–	2217
2022 Q4	$642K	Buy	+4,053	New	+$649K	﹤0.01%	1443
2022 Q2	–	Hold	0	–	–	–	1663

Man Group's RAPT Position: Q1 2026 in Review

Man Group sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 18,802 shares — an estimated $637K sold.

Man Group first reported a position in RAPT in Q4 2022 and held it in 2 quarters. The position peaked at $642K in Q4 2022. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

Man Group reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
Man Group sold 18,802 RAPT Therapeutics shares in Q1 2026, an estimated $637K.
Man Group first reported a position in RAPT Therapeutics in Q4 2022 and held it in 2 quarters.
Man Group's RAPT Therapeutics position peaked at $642K in Q4 2022.
0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.